Kong et al., 2020 - Google Patents
De novo development of proteolytically resistant therapeutic peptides for oral administrationKong et al., 2020
View PDF- Document ID
- 6318798671491745125
- Author
- Kong X
- Moriya J
- Carle V
- Pojer F
- Abriata L
- Deyle K
- Heinis C
- Publication year
- Publication venue
- Nature biomedical engineering
External Links
Snippet
The oral administration of peptide drugs is hampered by their metabolic instability and limited intestinal uptake. Here, we describe a method for the generation of small target- specific peptides (less than 1,600 Da in size) that resist gastrointestinal proteases. By using …
- 102000004196 processed proteins & peptides 0 title abstract description 111
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kong et al. | De novo development of proteolytically resistant therapeutic peptides for oral administration | |
Kale et al. | Cyclization of peptides with two chemical bridges affords large scaffold diversities | |
Heinis et al. | Phage-encoded combinatorial chemical libraries based on bicyclic peptides | |
Tal et al. | Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides | |
Bluntzer et al. | Designing stapled peptides to inhibit protein‐protein interactions: an analysis of successes in a rapidly changing field | |
Lyu et al. | Cryo-EM structures of a gonococcal multidrug efflux pump illuminate a mechanism of drug recognition and resistance | |
Baeriswyl et al. | Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases | |
US20150316536A1 (en) | Methods for screening | |
Barozzi et al. | Affibody-binding ligands | |
Credle et al. | Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries | |
Kong et al. | Generation of a large peptide phage display library by self-ligation of whole-plasmid PCR product | |
Niemann et al. | RNA type III secretion signals that require Hfq | |
King et al. | Selection for constrained peptides that bind to a single target protein | |
Diao et al. | Inhibition of Escherichia coli lipoprotein diacylglyceryl transferase is insensitive to resistance caused by deletion of Braun’s lipoprotein | |
WO2014103203A1 (en) | Molecule library constructed on the basis of backbone structure of microprotein | |
Wu et al. | Transcriptomic-proteomics-anticoagulant bioactivity integrated study of Pheretima guillemi | |
Lyu et al. | Structural basis of peptide-based antimicrobial inhibition of a resistance-nodulation-cell division multidrug efflux pump | |
Minomo et al. | Biological characteristics of two lysines on human serum albumin in the high‐affinity binding of 4Z, 15Z‐bilirubin‐IXα revealed by phage display | |
Zhang et al. | Analysis of HrpG regulons and HrpG‐interacting proteins by ChIP‐seq and affinity proteomics in Xanthomonas campestris | |
Keller et al. | Chemoproteomic identification of a DPP4 homolog in Bacteroides thetaiotaomicron | |
Rauh et al. | MS-based in situ proteomics reveals AMPylation of host proteins during bacterial infection | |
Qi et al. | Mirror-image protein and peptide drug discovery through mirror-image phage display | |
Brayden | Evolving peptides for oral intake | |
Kolářová et al. | De novo developed protein binders mimicking Interferon lambda signaling | |
Petty et al. | Binding interactions between the encephalomyocarditis virus leader and protein 2A |